Aavis Pharmaceuticals is a dynamic and rapidly expanding specialty pharmaceutical company. It focuses on the development, manufacturing, marketing, and distribution of both generic and branded pharmaceutical products. Key therapeutic areas for Aavis include Central Nervous System (CNS) disorders, Cardiovascular (CVS) conditions, anti-infectives, anti-inflammatories, and analgesics. The company is committed to providing high-quality, affordable medicines and innovative drug delivery solutions to improve patient outcomes.
Serves as the corporate headquarters for Aavis Pharmaceuticals, overseeing strategic direction, business development, marketing, distribution, and administrative functions for its U.S. and global operations.
Located in a modern corporate park in New Jersey's pharmaceutical hub, providing access to advanced office facilities. Specific architectural details are not publicly highlighted, but the environment supports collaborative and efficient business operations.
Aavis Pharmaceuticals fosters a culture centered on growth, innovation, quality, and integrity. The environment is likely dynamic and results-oriented, encouraging collaboration to expand the company's product portfolio and market presence in the pharmaceutical sector.
The Piscataway headquarters is strategically positioned within New Jersey's prominent pharmaceutical corridor. This location offers Aavis access to a rich talent pool, extensive industry networks, and proximity to key U.S. markets, serving as the central hub for decision-making and global strategy.
Aavis Pharmaceuticals operates with a global perspective, maintaining key facilities in the United States (New Jersey and Delaware) and an important operational hub in India (Hyderabad). The company's global functions include research and development collaborations, end-to-end product development, strategic manufacturing partnerships, international regulatory affairs, and the marketing and distribution of its diverse portfolio of pharmaceutical products across various international markets.
15 Corporate Place South, Suite # 420
Piscataway
New Jersey
USA
Address: 200 Continental Drive, Suite # 401, Newark, DE 19713, USA
Strategically located to leverage Delaware's growing biotech ecosystem and access scientific talent, this R&D center is crucial for Aavis's innovation and development of both generic and specialty pharmaceuticals.
Address: Specific street address not publicly listed, general location: Hyderabad
This office enables Aavis to tap into India's significant pharmaceutical talent pool, manage international supply chains, and expand its market access and operational footprint in the strategically important Asia-Pacific region.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Aavis Pharmaceuticals' leadership includes:
Aavis Pharmaceuticals has been backed by several prominent investors over the years, including:
Based on publicly available information, there have been no major announcements regarding executive hires or departures at Aavis Pharmaceuticals within the last 12 months. The current leadership team appears to be stable.
Discover the tools Aavis Pharmaceuticals uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
The common email formats for Aavis Pharmaceuticals are predicted based on standard industry patterns for companies with the domain 'aavispharma.com'. These are not officially confirmed and variations may exist.
[first_initial][last]@aavispharma.com (e.g., jdoe@aavispharma.com) or [first].[last]@aavispharma.com (e.g., jane.doe@aavispharma.com)
Format
vkavuru@aavispharma.com (example, based on a common pattern for executives)
Example
70%
Success rate
Aavis Pharmaceuticals Official Website • November 21, 2023
Aavis Pharmaceuticals announced its strategic acquisition of Burel Pharmaceutical, Inc. This move is set to expand Aavis's product portfolio and strengthen its market presence in various therapeutic categories....more
Aavis Pharmaceuticals Official Website • November 14, 2023
Reinforcing its commitment to growth and patient care, Aavis Pharmaceuticals announced the successful launch of three new pharmaceutical products, further diversifying its offerings in key therapeutic areas....more
GlobeNewswire • October 10, 2023
Aavis Pharmaceuticals entered into an agreement with Assertio Holdings, Inc. to acquire seven approved Abbreviated New Drug Applications (ANDAs) and one pending ANDA. This acquisition significantly bolsters Aavis's generic product pipeline....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Aavis Pharmaceuticals, are just a search away.